Researchers in the Perelman School of Medicine at the University of Pennsylvania have found a relationship between the genetics of tumors with germline BRCA1/2mutations—and whether the tumor retains the normal copy of the BRCA1/2 gene—and risk for primary resistance … Read more
PARP inhibitor Lynparza (olaparib) has been embraced by oncologists treating women with BRCA-mutant ovarian cancer, and the AstraZeneca drug is also showing promise in breast cancers that harbor the same mutations. But scientists led by the University of Pennsylvania believe … Read more
Myriad Genetics had been exclusively providing tests, for $3000+ a pop for full BRCA gene sequencing, for 17 years before the Supreme Court invalidated key gene patents back in 2013. Since the ruling a dozen or so competitors have been … Read more
Patients with relapsed BRCA-mutated ovarian cancer had a similar progression-free survival (PFS) with the PARP inhibitor rucaparib (Rubraca) regardless of the type of mutation, according to subgroup analyses of a prospective, multicenter trial.
Results showed a median PFS of … Read more
Over the past 20 years, Nazneen Rahman has identified a steady stream of genes that influence the risk of breast, ovarian, and childhood cancers—work that has earned her scientific, popular, and even royal acclaim. But her latest accomplishment, and one … Read more